Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | TTK | P33981 | 2/20 | 0.48 |
| ▸ | ITK | Q08881 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423200 | 0.90 | APP (0.57) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL1422651 | 0.83 | SMN1; SMN2 (0.48) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL1421592 | 0.83 | TDO2 (0.53) | MAPTAPPITKSMN1; SMN2 | |
| SCHEMBL1420994 | 0.82 | CYP19A1 (0.52) | MAPTAPPCCNA2CDK2CCNT1 | |
| SCHEMBL3299142 | 0.82 | CDK5 (0.56) | MAPTAPPRIPK1 | |
| SCHEMBL13577803 | 0.82 | MAPT (0.44) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL1422905 | 0.82 | KDM4E (0.59) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL4264688 | 0.79 | KDM4E (0.81) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL1421172 | 0.79 | CYP19A1 (0.58) | MAPTITKCCNB2CDK1CCNB1 | |
| SCHEMBL1484630 | 0.76 | KDM4E (0.56) | KDM4ENPC1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | APP, IDO2, IDO1 | KDM4E 2008/4885NPC1 335/4885RAB9A 2477/4885 |
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | KDM4E 1666/4885NPC1 228/4885RAB9A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.